MP-0310 is under clinical development by Molecular Partners and currently in Phase I for Cutaneous Squamous Cell Carcinoma (cSCC). According to GlobalData, Phase I drugs for Cutaneous Squamous Cell Carcinoma (cSCC) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how MP-0310’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MP-0310 overview

MP-0310 is under development for the treatment of solid tumors including colorectal cancer, ovarian cancer, endometrial cancer, gastric cancer, pancreatic cancer, anal cancer, cervical cancer, squamous cell cancer of the head and neck, breast cancer, mesothelioma, prostate cancer, non-small cell lung cancer, melanoma, urothelial or bladder cancer, microsatellite tumors and cutaneous squamous cell carcinoma. The drug candidate is administered through intravenous route. It is a multi-DARPin and a tumor-restricted T-cell co-stimulator. It targets 4-1BB (CD137) protein mainly expressed on activated CD4+ and CD8+ T cells, activated B cells, and natural killer (NK) cells and fibroblast activating protein (FAP) which is expressed in stroma of many tumor cells. It is developed based on DARPin technology.

Molecular Partners overview

Molecular Partners is a clinical-stage biopharmaceutical company that develops biological drugs. The company offers advanced small protein therapies such as abicipar, a designed ankyrin repeat protein-based anti-angiogenic drug developed for diabetic macular edema and wet age-macular degeneration. Its product pipeline includes MP0317- FAP x CD40, MP0533 -CD3 x CD33+CD70+CD123 and sars-cov-2: COVID. Molecular Partners develops products for ophthalmic conditions, cancer, immune disorders and other indications It also develops drugs on DARPin base technology and other product candidates. The company also provides clinical trial services and small protein therapies. Molecular Partners is headquartered in Zurich, Switzerland.

For a complete picture of MP-0310’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.